ArticleMolecular and cellular neurosciences2010
Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin-treated neonatal rats.
Article in Molecular and cellular neurosciences, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Pooled it
- Rodent Models of Retinal Degeneration: From Purified Cells in Culture to Living Animals.Cold Spring Harbor perspectives in medicine · 2024Review
- Taurine: a promising nutraceutic in the prevention of retinal degeneration.Neural regeneration research · 2024Review
- Pharmacokinetics and tissue distribution of vigabatrin enantiomers in rats.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Testing for pharmacogenomic predictors of ppRNFL thinning in individuals exposed to vigabatrin.Frontiers in neuroscience · 2023Article
- Vitamin A aldehyde-taurine adducts function in photoreceptor cells.Redox biology · 2022Article
- Therapeutic effect of the mesenchymal stem cells on vigabatrin-induced retinopathy in adult male albino rat.Anatomy & cell biology · 2022Article
- Early vigabatrin augmenting GABA-ergic pathways in post-anoxic status epilepticus (VIGAB-STAT) phase IIa clinical trial study protocol.Neurological research and practice · 2022Article
- Glial Cell Activation and Oxidative Stress in Retinal Degeneration Induced by β-Alanine Caused Taurine Depletion and Light Exposure.International journal of molecular sciences · 2021Article
- Vigabatrin-Induced Retinal Functional Alterations and Second-Order Neuron Plasticity in C57BL/6J Mice.Investigative ophthalmology & visual science · 2020Article
- Gyrate atrophy-like phenotype with normal plasma ornithine and low plasma taurine.GMS ophthalmology cases · 2020Article
- Systemic taurine treatment provides neuroprotection against retinal photoreceptor degeneration and visual function impairments.Drug design, development and therapy · 2019Article
- Rational Basis for Nutraceuticals in the Treatment of Glaucoma.Current neuropharmacology · 2018Review
- Evaluation of inner retinal layers with optic coherence tomography in vigabatrin-exposed patients.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
- mTOR Inhibition Mitigates Molecular and Biochemical Alterations of Vigabatrin-Induced Visual Field Toxicity in Mice.Pediatric neurology · 2017Article
- Vigabatrin can enhance electroretinographic responses in pigmented and albino rats.Documenta ophthalmologica. Advances in ophthalmology · 2015Article
- Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study.Neurology · 2014Observational
- Recent advances in the pharmacotherapy of infantile spasms.CNS drugs · 2014Review
- Taurine trial in succinic semialdehyde dehydrogenase deficiency and elevated CNS GABA.Neurology · 2014Article
- Latest American and European updates on infantile spasms.Current neurology and neuroscience reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
The anti-epileptic drug vigabatrin induces an irreversible constriction of the visual field, but is still widely used to treat infantile spasms and some forms of epilepsy. We recently reported that vigabatrin-induced cone damage is due to a taurine deficiency. However, optic atrophy and thus retinal ganglion cell degeneration was also reported in children treated for infantile spasms. We here show in neonatal rats treated from postnatal days 4 to 29 that the vigabatrin treatment triggers not only cone photoreceptor damage, disorganisation of the photoreceptor layer and gliosis but also retinal ganglion cell loss. Furthermore, we demonstrate in these neonatal rats that taurine supplementation partially prevents these retinal lesions and in particular the retinal ganglion cell loss. These results provide the first evidence of retinal ganglion cell neuroprotection by taurine. They further confirm that taurine supplementation should be administered with the vigabatrin treatment for infantile spasms or epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.